Bristol-Myers Squibb Company / Immatics N.V.

MAGEA4/8-Positive Solid Tumors (TCR-Bispecific T-Cell Engagement)

50K US cases/yr · $35.0B Global solid-tumor immuno-oncology market (2021) · 40-45% U.S. HLA-A*02:01 allele frequency (addressable subset)

Disease Overview

MAGE-A4 and MAGE-A8 are cancer-testis antigens aberrantly expressed in approximately 25-50% of solid tumors including squamous non-small cell lung cancer (~25-40% MAGE-A4 positivity in HLA-A*02:01 patients), melanoma (~30-50%), head and neck squamous cell carcinoma (~30-40%), urothelial carcinoma (~20-25%), synovial sarcoma (~70-80%), ovarian cancer (~25-35%), and esophageal squamous cell carcinoma (~30-50%). The HLA-A*02:01-restricted addressable U.S. patient population — accounting for the ~40-45% U.S. HLA-A2 prevalence and tumor-type MAGE-A4 expression rate — is approximately 50,000-70,000 patients per year across these indications combined. The clinical paradigm of choice has been autologous T-cell therapy (Adaptimmune's afami-cel/Tecelra in synovial sarcoma, FDA approved Aug 2024) and engineered TCR therapeutics, but Immatics' TCER (TCR Bispecific) approach is mechanistically distinct — an off-the-shelf bispecific that simultaneously engages MAGE-A4/8-loaded HLA-A*02:01 on tumor cells and CD3 on endogenous T-cells, eliminating the need for autologous cell engineering. Commercial opportunity is anchored in HLA-A*02:01-positive squamous lung, melanoma, head/neck and other MAGE-A4/8-expressing tumors where standard checkpoint and chemotherapy options have plateaued.

Competitive Landscape

The MAGE-A4 competitive landscape is anchored on three differentiated platforms. Engineered autologous TCR-T therapy is led by Adaptimmune's afami-cel (Tecelra, FDA approved August 2024 for synovial sarcoma) — the first engineered TCR-T approved in solid tumors, marketed at a list price exceeding $700,000 per dose with a complex logistics footprint. Immatics' TCER bispecific approach (IMA401 for MAGE-A4/8, IMA402 for PRAME) is mechanistically off-the-shelf, IV-infusible, and positions against autologous TCR-T economics. PRAME-targeted bispecifics (Immunocore IMC-F106C/brenetafusp, BMS via brenetafusp) and bispecific TCRs targeting MAGE-A4 (Adaptimmune ADP-A2M4-CD8) compete in adjacent settings. Other MAGE-A4 strategies include CAR-T constructs and CRISPR-edited T-cell platforms (Caribou, Editas). The Bristol Myers Squibb-Immatics partnership for IMA401 was terminated by mutual agreement in November 2023 after a portfolio review, with Immatics regaining full global rights — leaving the asset development on Immatics' balance sheet and opening BMS to alternative platform plays through its Cellares and other oncology cell-therapy investments.